KRAS-Targeted PROTAC Degraders are Broadly Efficacious Against KRAS Dependent Tumor Models Read More »
High throughput screening techniques to inform on compound liability and solubility to advance the PROTAC® platform Read More »
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – Poster Presentation Read More »
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – PLS Read More »
The Arvinas PROTAC® Discovery Engine: Insights from Discovering & Developing Molecules That Induce Targeted Protein Degradation Read More »
ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study Read More »
Outcomes in men with metastatic castration-resistant prostate cancer and tumors with certain androgen receptor (AR) mutations Read More »
Real world outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations Read More »
In Vitro Evaluation Of PROTAC® Degrader ARV-110 (Bavdegalutamide) For Cytochrome P450- And Transporter-Mediated Drug-Drug Interaction Read More »
